KenvueKVUE
Market Cap: $43.8B
About: Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Employees: 22,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
82% more call options, than puts
Call options by funds: $283M | Put options by funds: $156M
30% more repeat investments, than reductions
Existing positions increased: 424 | Existing positions reduced: 326
24% more first-time investments, than exits
New positions opened: 134 | Existing positions closed: 108
3% more funds holding
Funds holding: 947 [Q1] → 973 (+26) [Q2]
0.62% less ownership
Funds ownership: 98.69% [Q1] → 98.07% (-0.62%) [Q2]
12% less funds holding in top 10
Funds holding in top 10: 17 [Q1] → 15 (-2) [Q2]
16% less capital invested
Capital invested by funds: $40.5B [Q1] → $34.1B (-$6.38B) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
JP Morgan Andrea Teixeira 53% 1-year accuracy 32 / 60 met price target | 5%upside $24 | Overweight Maintained | 7 Aug 2024 |
Deutsche Bank Steve Powers 93% 1-year accuracy 13 / 14 met price target | 5%upside $24 | Buy Maintained | 7 Aug 2024 |
RBC Capital Nik Modi 58% 1-year accuracy 22 / 38 met price target | 5%upside $24 | Outperform Reiterated | 7 Aug 2024 |
UBS Peter Grom 50% 1-year accuracy 7 / 14 met price target | 4%downside $22 | Neutral Maintained | 7 Aug 2024 |
Deutsche Bank Steve Powers 93% 1-year accuracy 13 / 14 met price target | 1%upside $23 | Buy Maintained | 25 Jul 2024 |
Financial journalist opinion
Based on 12 articles about KVUE published over the past 30 days